来自专业的译者、企业、网页和免费的翻译库。
tagrisso 40 mg pilloli osimertinib
tagrisso 40 mg tablets osimertinib
最后更新: 2017-04-26
使用频率: 2
质量:
fih is-sustanza attiva osimertinib.
it contains the active substance osimertinib.
最后更新: 2017-04-26
使用频率: 1
质量:
tagrisso 40 mg pilloli miksijin b’rita osimertinib
tagrisso 40 mg film-coated tablets osimertinib
最后更新: 2017-04-26
使用频率: 2
质量:
l-effetti ta' osimertinib fuq p-gp u bcrp
effects of osimertinib on p-gp and bcrp
最后更新: 2017-04-26
使用频率: 1
质量:
kull pillola fiha 40 mg osimertinib (bħala mesylate).
each tablet contains 40 mg osimertinib (as mesylate).
最后更新: 2017-04-26
使用频率: 2
质量:
is-sustanza attiva hija osimertinib (bħala mesylate).
the active substance is osimertinib (as mesylate).
最后更新: 2017-04-26
使用频率: 1
质量:
osimertinib jista' jżid l- espożizzjoni tas-sottostrati ta' bcrp.
osimertinib may increase the exposure of bcrp substrates.
最后更新: 2017-04-26
使用频率: 1
质量:
osimertinib ma kkawżax ħsara ġenetika f'assaġġi in vitro u in vivo.
osimertinib did not cause genetic damage in in vitro and in vivo assays.
最后更新: 2017-04-26
使用频率: 1
质量:
effett ta' sustanzi attivi li jnaqqsu l-aċidu gastriku fuq osimertinib
effect of gastric acid reducing active substances on osimertinib
最后更新: 2017-04-26
使用频率: 1
质量:
studji in vitro jindikaw li osimertinib huwa prinċipalment metabolizzat minn cyp3a4, u cyp3a5.
in vitro studies indicate that osimertinib is metabolized predominantly by cyp3a4, and cyp3a5.
最后更新: 2017-04-26
使用频率: 1
质量:
indutturi qawwija ta' cyp3a4 jistgħu jnaqqsu l-espożizzjoni ta' osimertinib.
strong cyp3a4 inducers can decrease the exposure of osimertinib.
最后更新: 2017-04-26
使用频率: 1
质量:
osimertinib huwa inibitur ta' tyrosine kinase (tyrosine kinase inhibitor, tki).
osimertinib is a tyrosine kinase inhibitor (tki).
最后更新: 2017-04-26
使用频率: 1
质量:
abbażi ta' studji in vitro, osimertinib huwa inibitur kompetittiv tat-trasportaturi ta' bcrp.
based on in vitro studies, osimertinib is a competitive inhibitor of bcrp transporters.
最后更新: 2017-04-26
使用频率: 1
质量:
għalhekk, mhuwiex probabbli li l-inibituri ta' cyp3a4 jaffettwaw l-espożizzjoni għal osimertinib.
therefore, cyp3a4 inhibitors are not likely to affect the exposure of osimertinib.
最后更新: 2017-04-26
使用频率: 1
质量:
ecgs serjali nġabru wara doża unika u fi stat fiss biex jiġi evalwat l-effett ta' osimertinib fl-intervalli qtc.
serial ecgs were collected following a single dose and at steady-state to evaluate the effect of osimertinib on qtc intervals.
最后更新: 2017-04-26
使用频率: 1
质量:
abbażi ta' dejta in vitro, osimertinib huwa inibitur ta' bcrp. (ara sezzjoni 4.5).
based on in vitro data, osimertinib is an inhibitor of bcrp and
最后更新: 2017-04-26
使用频率: 1
质量:
fi studju modifikat dwar l-iżvilupp embrijofetali fil-firien, osimertinib ikkawża embrijoletalità meta ngħata lil firien tqal qabel impjantazzjoni embrijonika.
in a modified embryofoetal development study in the rat, osimertinib caused embryolethality when administered to pregnant rats prior to embryonic implantation.
最后更新: 2017-04-26
使用频率: 1
质量:
in vitro, osimertinib ma jinibixxix p-glycoprotein, oat1, oat3, oatp1b1, oatp1b3 u mate2k f'konċentrazzjonijiet klinikament relevanti.
in vitro, osimertinib does not inhibit oat1, oat3, oatp1b1, oatp1b3 and mate2k at clinically relevant concentrations.
最后更新: 2017-04-26
使用频率: 1
质量:
abbażi ta' studji in vitro, osimertinib mhuwiex inibitur ta' ugt1a1 u ugt2b7 f'konċentrazzjonijiet klinikament rilevanti fil-fwied.
based on in vitro studies, osimertinib is not an inhibitor of ugt1a1 and ugt2b7 at clinically relevant concentrations hepatically.
最后更新: 2017-04-26
使用频率: 1
质量:
fi studji kliniku farmakokinetiku, l-għoti flimkien ta' omeprazole ma rriżultax f'tibdil klinikament rilevanti fl-espożizzjonijiet għal osimertinib.
in a clinical pharmacokinetic study, co-administration of omeprazole did not result in clinically relevant changes in osimertinib exposures.
最后更新: 2017-04-26
使用频率: 1
质量: